A Covid-19 provocou profundas mudanças na organização da sociedade e nas áreas científica e tecnológica. Publicações e interações geradoras de conhecimento resultaram em uma quantidade inédita de artigos científicos, patentes, produtos e serviços disponibilizados rapidamente no mercado. Por meio da prospecção patentária nas bases de dados Orbit Intelligence® (Questel), Espacenet e do INPI, foram recuperados e analisados documentos de patente sob propriedade da Fiocruz, com o objetivo de avaliar o impacto da pandemia no número e perfil de patentes depositadas pela instituição. Os resultados indicam potencial contribuição de cerca de 11,5% de patentes originadas a partir dos esforços e respostas à emergência sanitária provocada pelo novo coronavírus em relação ao total de patentes da Fiocruz, concretizando ainda mais o protagonismo da instituição no enfrentamento da pandemia e o legado para a sociedade brasileira.
Introduction: Bio-Manguinhos has been establishing systematic Technology Foresight (TF), based on the experience acquired in TF focused on plant platform, later in 2018, as one of the strategies for tackling the COVID-19 pandemic. TF is an ongoing process that aims to map projects and products under development for COVID-19 (vaccines, biopharmaceuticals and diagnostics) in a worldwide framework.Objective: To present the TF initiatives regarding the design of the process and its use as a tool to analyze the current COVID-19 scenario. Methodology:To establish and design a TF process, the starting research questions were: "which are the products under development for COVID-19", "what are their development status" and "which organizations are involved". To address those questions, a multidisciplinary network was established in Bio-Manguinhos with Foresight Groups (FG), Discussion Groups (DG) and Opportunities Group (OG). Given the specificities of each segment, three subgroups were created for vaccines, biopharmaceuticals, and diagnostics, with FG, DG e OG participants. The FG collected data from different databases and websites to identify product pipelines, projects, clinical studies, technologies, patents, and scientific publications (including articles, preprints, newsletter and press releases). For data preparation, the FG set up different data transformation strategies, creating proprietary data tables. For analysis and visualization, the FG used data mining and descriptive statistics in Microsoft Excel® and Power BI®. In parallel, to improve data enrichment, the FG and DG worked closely to discuss and study scientific publications and clinical trials and interacted with OG to streamline scenario analyzes to subsidize negotiations and partnerships. Results:The result of this work is three-fold: agile scenario building and analysis to support decision making regarding COVID-19 product partnerships; improvement of a previous foresight process used for plant-based technologies; the development of a structured data tables covering more than 900 development initiatives in the three Bio-Manguinhos product lines since the beginning of COVID-19 pandemic. The data enrichment applied during the treatment step allowed to analyze product and technological platforms, technology details and respective development phases, geographical localization of R&D efforts, networks of collaboration, players, and market positioning strategies. Conclusion:Besides contributing to support and improve Bio-Manguinhos technological decisions regarding COVID-19, as an integral part of the ongoing efforts has also improved technological decision making based on foresight approaches. The methodological improvement and additional techniques adopted to address the COVID-19 pandemics hasn't only contributed to consolidate the knowledge accumulated in previous foresight initiatives but has also stimulated the design of a proprietary database, whose conceptual model is tailored to the different kind of data and information. Besides demonstrating the ...
Introduction: The Brazilian Genetic Heritage Act (13.123) was enforced on November 2015. It seeks to protect and to encourage the sustainable use of Brazilian biodiversity. The Act defines Genetic Heritage (GH) as information on the genetic origin of vegetal, animal and microbial species, or species of other nature, and on the substances derived from the metabolism of those living beings. Therefore, the Act encompasses every scientific activity utilizing viruses/ bacteria/fungi which have been collected from Brazilian individuals or endogenous animals; Brazilian genetic sequences from GenBank®; in silico research of endogenous viruses/bacteria/ fungi; microorganisms engineered with endogenous genetic sequences; antibodies produced by endogenous animals, domesticated species and spontaneous populations found in Brazilian territory. Among the legal demands there is a mandatory registration in the National System for the Management of Genetic Heritage and Associated Traditional Knowledge (SisGen) prior to the disclosure of either final or parcial results of researches using endogenous GH. Objective: To evaluate the impact of the Brazilian Genetic Heritage Act on Bio-Manguinhos' scientific publications. Therefore, this abstract addresses the role of Bio-Manguinhos through its Office of Technology Transfer (NIT-Bio) on the regularization/registration of dissertations from the Professional Master Course in Immunobiological Technology (MPTI) and abstracts from the Annual Scientific and Technological Seminar (SACT) whenever they address genetic heritage. Methodology: In this evaluation, the dissertations submitted to the MPTI (2003 through 2015) as well as the abstracts submitted to the SACT (2013 through 2018) were verified by NIT-Bio in order to identify the access to genetic heritage. Each dissertation/abstract was read, performing a case-by-case evaluation. When doubts have arisen, they were forwarded to Fiocruz's Genetic Heritage Work Group to solution. The authors of the selected dissertations/abstracts were informed by e-mail and were guided to proceed the regularization (for GH access initiated before November 17 th , 2015) or the registration (for GH access initiated after November 17 th , 2015) on SisGen, with NIT-Bio guidance. Results: Within the selected periods, 32 dissertations out of a 121 from MPTI had accessed the Brazilian GH (26%). Out of the 418 abstracts from SACT, 289 were elaborated by Bio-Manguinhos employees, amongst them, only 93 have accessed the Brazilian GH (32%). As a result, 23 registrations and 16 regularizations entered the SisGen. It should be noted that registrations and regularizations had more than one dissertation or abstract. Conclusion: The access to the Brazilian Genetic Heritage occurred in 26% of the dissertations submitted to MPTI and in 32% of the abstracts submitted to SACT, indicating that the Brazilian Genetic Heritage Act impacts on. Therefore, researchers should follow the institutional guidance regarding scientific publications involving Brazilian GH in order to avoid th...
Introduction: As an example of many of technology foresight (TF) applications, it can help an organization to identify areas to concentrate research and development investments in short, medium and long terms. Since 2012, Bio-Manguinhos (BM) has been investing in plant-based technologies. This is an emerging field, with few registered products and only one in the market. Therefore, establishing a systematic TF will contribute to BM' decisionmaking for target selection and project prioritization to be further advanced at the Plant Based Technology Center. Objective: To present the results of ongoing in-house TF initiatives in molecular pharming regarding the design of the process, as well the data and analyses so far obtained about the current scenario and trends in the area. Methodology: To establish and design a TF process, we identified the main areas and business processes and interviewed main stakeholders. Regarding the application of TF methods, we used Medtrack® to identify the pipeline of 22 companies working in molecular pharming, covering biotherapeutics and vaccine. Since there was no suitable database available in BM for diagnostics, we searched scientific databases (Embase®, Scopus®, Web of Science® and Pubmed®) and a patent database (Derwent Innovations Index®). To clean, classify and analyze the results, we used data mining, descriptive statistics in Microsoft Excel®, Tableau® and Vantage Point® software. Results: We were able to identify the major requirements and methods that could be currently applied in BM for early search and selection of targets. Regarding the TF results, the Medtrack® search retrieved 84 plant-based biotherapeutics (market phase, N= 1; phase III, N= 2) by 14 companies. Transient Expression Systems (TES) were the source of 48.8% of these products. For plant-based vaccines, five companies had 22 products under research (phase III, N= 1), all of which obtained by TES. For diagnostics, three out of 18 publications mentioned products obtained by TES. Regarding patents, nine out of 1,095 original documents were selected for further analyses due to their relevance. Four of these patents were related to at least one of the 18 original publications, but no products were identified on the specific market. Conclusion: In general, we demonstrated that TES is a broad range expression system and can be the best choice for many targets. However, the market database and the search of scientific and patents databases did not add to the existing knowledge of vaccines and diagnostics products in market players, respectively. For vaccines and biotherapeutics, the use of scientific and patent information is also necessary to complement the analysis and for diagnostics, other foresight techniques are required. Besides an overall view of trends and potential areas of interest, this work also demonstrates the importance of institutionalizing TF. Further work is necessary to improve the data gathering as well as data analytics.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.